Adverse outcome pathways

opportunities, limitations and open questions

Marcel Leist, Ahmed Ghallab, Rabea Graepel, Rosemarie Marchan, Reham Hassan, Susanne Hougaard Bennekou, Alice Limonciel, Mathieu Vinken, Stefan Schildknecht, Tanja Waldmann, Erik Danen, Ben van Ravenzwaay, Hennicke Kamp, Iain Gardner, Patricio Godoy, Frederic Y. Bois, Albert Braeuning, Raymond Reif, Franz Oesch, Dirk Drasdo & 33 others Stefan Höhme, Michael Schwarz, Thomas Hartung, Thomas Braunbeck, Joost Beltman, Harry Vrieling, Ferran Sanz, Anna Forsby, Domenico Gadaleta, Ciarán Fisher, Jens Kelm, David Fluri, Gerhard Ecker, Barbara Zdrazil, Andrea Terron, Paul Jennings, Bart van der Burg, Steven Dooley, Annemarie H. Meijer, Egon Willighagen, Marvin Martens, Chris Evelo, Enrico Mombelli, Olivier Taboureau, Alberto Mantovani, Barry Hardy, Bjorn Koch, Sylvia Escher, Christoph van Thriel, Cristina Cadenas, D. Kroese, Bob van de Water, Jan G. Hengstler

Research output: Contribution to journalArticle

Abstract

Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.

Original languageEnglish (US)
Pages (from-to)3477-3505
Number of pages29
JournalArchives of Toxicology
Volume91
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Metabolism
Toxicology
Plasticity
History
Weights and Measures

Keywords

  • Binning of events
  • CCl
  • Computational toxicology
  • Interspecies extrapolation
  • Liver fibrosis
  • Metabolism
  • Multi-scale integration
  • Multiple hit events
  • Paracetamol
  • Pathway unidirectionality
  • Prioritization of compounds
  • Proof of non-toxicity
  • Regulatory toxicology
  • Systems biology
  • Tumor promotion
  • Vinyl acetate

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Leist, M., Ghallab, A., Graepel, R., Marchan, R., Hassan, R., Bennekou, S. H., ... Hengstler, J. G. (2017). Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology, 91(11), 3477-3505. https://doi.org/10.1007/s00204-017-2045-3

Adverse outcome pathways : opportunities, limitations and open questions. / Leist, Marcel; Ghallab, Ahmed; Graepel, Rabea; Marchan, Rosemarie; Hassan, Reham; Bennekou, Susanne Hougaard; Limonciel, Alice; Vinken, Mathieu; Schildknecht, Stefan; Waldmann, Tanja; Danen, Erik; van Ravenzwaay, Ben; Kamp, Hennicke; Gardner, Iain; Godoy, Patricio; Bois, Frederic Y.; Braeuning, Albert; Reif, Raymond; Oesch, Franz; Drasdo, Dirk; Höhme, Stefan; Schwarz, Michael; Hartung, Thomas; Braunbeck, Thomas; Beltman, Joost; Vrieling, Harry; Sanz, Ferran; Forsby, Anna; Gadaleta, Domenico; Fisher, Ciarán; Kelm, Jens; Fluri, David; Ecker, Gerhard; Zdrazil, Barbara; Terron, Andrea; Jennings, Paul; van der Burg, Bart; Dooley, Steven; Meijer, Annemarie H.; Willighagen, Egon; Martens, Marvin; Evelo, Chris; Mombelli, Enrico; Taboureau, Olivier; Mantovani, Alberto; Hardy, Barry; Koch, Bjorn; Escher, Sylvia; van Thriel, Christoph; Cadenas, Cristina; Kroese, D.; van de Water, Bob; Hengstler, Jan G.

In: Archives of Toxicology, Vol. 91, No. 11, 01.11.2017, p. 3477-3505.

Research output: Contribution to journalArticle

Leist, M, Ghallab, A, Graepel, R, Marchan, R, Hassan, R, Bennekou, SH, Limonciel, A, Vinken, M, Schildknecht, S, Waldmann, T, Danen, E, van Ravenzwaay, B, Kamp, H, Gardner, I, Godoy, P, Bois, FY, Braeuning, A, Reif, R, Oesch, F, Drasdo, D, Höhme, S, Schwarz, M, Hartung, T, Braunbeck, T, Beltman, J, Vrieling, H, Sanz, F, Forsby, A, Gadaleta, D, Fisher, C, Kelm, J, Fluri, D, Ecker, G, Zdrazil, B, Terron, A, Jennings, P, van der Burg, B, Dooley, S, Meijer, AH, Willighagen, E, Martens, M, Evelo, C, Mombelli, E, Taboureau, O, Mantovani, A, Hardy, B, Koch, B, Escher, S, van Thriel, C, Cadenas, C, Kroese, D, van de Water, B & Hengstler, JG 2017, 'Adverse outcome pathways: opportunities, limitations and open questions', Archives of Toxicology, vol. 91, no. 11, pp. 3477-3505. https://doi.org/10.1007/s00204-017-2045-3
Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH et al. Adverse outcome pathways: opportunities, limitations and open questions. Archives of Toxicology. 2017 Nov 1;91(11):3477-3505. https://doi.org/10.1007/s00204-017-2045-3
Leist, Marcel ; Ghallab, Ahmed ; Graepel, Rabea ; Marchan, Rosemarie ; Hassan, Reham ; Bennekou, Susanne Hougaard ; Limonciel, Alice ; Vinken, Mathieu ; Schildknecht, Stefan ; Waldmann, Tanja ; Danen, Erik ; van Ravenzwaay, Ben ; Kamp, Hennicke ; Gardner, Iain ; Godoy, Patricio ; Bois, Frederic Y. ; Braeuning, Albert ; Reif, Raymond ; Oesch, Franz ; Drasdo, Dirk ; Höhme, Stefan ; Schwarz, Michael ; Hartung, Thomas ; Braunbeck, Thomas ; Beltman, Joost ; Vrieling, Harry ; Sanz, Ferran ; Forsby, Anna ; Gadaleta, Domenico ; Fisher, Ciarán ; Kelm, Jens ; Fluri, David ; Ecker, Gerhard ; Zdrazil, Barbara ; Terron, Andrea ; Jennings, Paul ; van der Burg, Bart ; Dooley, Steven ; Meijer, Annemarie H. ; Willighagen, Egon ; Martens, Marvin ; Evelo, Chris ; Mombelli, Enrico ; Taboureau, Olivier ; Mantovani, Alberto ; Hardy, Barry ; Koch, Bjorn ; Escher, Sylvia ; van Thriel, Christoph ; Cadenas, Cristina ; Kroese, D. ; van de Water, Bob ; Hengstler, Jan G. / Adverse outcome pathways : opportunities, limitations and open questions. In: Archives of Toxicology. 2017 ; Vol. 91, No. 11. pp. 3477-3505.
@article{924fdf4f439944b684249308040f9fca,
title = "Adverse outcome pathways: opportunities, limitations and open questions",
abstract = "Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.",
keywords = "Binning of events, CCl, Computational toxicology, Interspecies extrapolation, Liver fibrosis, Metabolism, Multi-scale integration, Multiple hit events, Paracetamol, Pathway unidirectionality, Prioritization of compounds, Proof of non-toxicity, Regulatory toxicology, Systems biology, Tumor promotion, Vinyl acetate",
author = "Marcel Leist and Ahmed Ghallab and Rabea Graepel and Rosemarie Marchan and Reham Hassan and Bennekou, {Susanne Hougaard} and Alice Limonciel and Mathieu Vinken and Stefan Schildknecht and Tanja Waldmann and Erik Danen and {van Ravenzwaay}, Ben and Hennicke Kamp and Iain Gardner and Patricio Godoy and Bois, {Frederic Y.} and Albert Braeuning and Raymond Reif and Franz Oesch and Dirk Drasdo and Stefan H{\"o}hme and Michael Schwarz and Thomas Hartung and Thomas Braunbeck and Joost Beltman and Harry Vrieling and Ferran Sanz and Anna Forsby and Domenico Gadaleta and Ciar{\'a}n Fisher and Jens Kelm and David Fluri and Gerhard Ecker and Barbara Zdrazil and Andrea Terron and Paul Jennings and {van der Burg}, Bart and Steven Dooley and Meijer, {Annemarie H.} and Egon Willighagen and Marvin Martens and Chris Evelo and Enrico Mombelli and Olivier Taboureau and Alberto Mantovani and Barry Hardy and Bjorn Koch and Sylvia Escher and {van Thriel}, Christoph and Cristina Cadenas and D. Kroese and {van de Water}, Bob and Hengstler, {Jan G.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s00204-017-2045-3",
language = "English (US)",
volume = "91",
pages = "3477--3505",
journal = "Archiv fur Toxikologie",
issn = "0003-9446",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Adverse outcome pathways

T2 - opportunities, limitations and open questions

AU - Leist, Marcel

AU - Ghallab, Ahmed

AU - Graepel, Rabea

AU - Marchan, Rosemarie

AU - Hassan, Reham

AU - Bennekou, Susanne Hougaard

AU - Limonciel, Alice

AU - Vinken, Mathieu

AU - Schildknecht, Stefan

AU - Waldmann, Tanja

AU - Danen, Erik

AU - van Ravenzwaay, Ben

AU - Kamp, Hennicke

AU - Gardner, Iain

AU - Godoy, Patricio

AU - Bois, Frederic Y.

AU - Braeuning, Albert

AU - Reif, Raymond

AU - Oesch, Franz

AU - Drasdo, Dirk

AU - Höhme, Stefan

AU - Schwarz, Michael

AU - Hartung, Thomas

AU - Braunbeck, Thomas

AU - Beltman, Joost

AU - Vrieling, Harry

AU - Sanz, Ferran

AU - Forsby, Anna

AU - Gadaleta, Domenico

AU - Fisher, Ciarán

AU - Kelm, Jens

AU - Fluri, David

AU - Ecker, Gerhard

AU - Zdrazil, Barbara

AU - Terron, Andrea

AU - Jennings, Paul

AU - van der Burg, Bart

AU - Dooley, Steven

AU - Meijer, Annemarie H.

AU - Willighagen, Egon

AU - Martens, Marvin

AU - Evelo, Chris

AU - Mombelli, Enrico

AU - Taboureau, Olivier

AU - Mantovani, Alberto

AU - Hardy, Barry

AU - Koch, Bjorn

AU - Escher, Sylvia

AU - van Thriel, Christoph

AU - Cadenas, Cristina

AU - Kroese, D.

AU - van de Water, Bob

AU - Hengstler, Jan G.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.

AB - Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.

KW - Binning of events

KW - CCl

KW - Computational toxicology

KW - Interspecies extrapolation

KW - Liver fibrosis

KW - Metabolism

KW - Multi-scale integration

KW - Multiple hit events

KW - Paracetamol

KW - Pathway unidirectionality

KW - Prioritization of compounds

KW - Proof of non-toxicity

KW - Regulatory toxicology

KW - Systems biology

KW - Tumor promotion

KW - Vinyl acetate

UR - http://www.scopus.com/inward/record.url?scp=85031799653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031799653&partnerID=8YFLogxK

U2 - 10.1007/s00204-017-2045-3

DO - 10.1007/s00204-017-2045-3

M3 - Article

VL - 91

SP - 3477

EP - 3505

JO - Archiv fur Toxikologie

JF - Archiv fur Toxikologie

SN - 0003-9446

IS - 11

ER -